We are pioneering innovative therapies to combat new strains of influenza, flu, and other enveloped viruses, aiming to prevent viral entry and infection in human and animal cells. Mechanism of action involves binding to the viral spike protein, effectively blocking its interaction with host cell receptors and stopping the infection process. Designed to address the urgent challenges posed by emerging viral strains, our drug offers a rapid and effective solution, bridging the critical time gap before vaccines and other therapies become available.